Safety and efficacy of neoadjuvant S-1 and oxaliplatin therapy for gastric cancer in the elderly: combined phase II trials of KSCC1601 and KSCC1801.

Authors

Keiichiro Ryujin, Kojiro Shirabe, Shota Sato, Akihiko Otake, Yuki Shin, Keita Natsugoe, Tetsuro Kawazoe, Sho Nambara, Yasuo Tsuda, Tomonori Nakanoko, Koji Ando, Mitsuhiko Ota, Masaaki Iwatsuki, Hiroshi Saeki, Tomoharu Yoshizumi, Eiji Oki

Published in

International journal of clinical oncology. Oct 20, 2026. Epub Oct 20, 2026.

Abstract

The efficacy of neoadjuvant chemotherapy in elderly patients with locally advanced gastric cancer remains unclear. We evaluated neoadjuvant S-1 plus oxaliplatin (SOX) therapy in elderly patients using patient data from two phase II trials.
Patient data from KSCC1601 and KSCC1801 phase II trials were integrated. Patients were divided into an elderly group (age ≥75 years) and a non-elderly group (age <75 years). Adverse events, postoperative complications, and outcomes were compared. Overall survival (OS) and recurrence-free survival (RFS) were calculated from treatment initiation.
Among the 73 patients enrolled in trials, 66 (90.4%) underwent surgery and 65 (89.0%) achieved R0 resection. Neoadjuvant SOX therapy was administered to 69 patients (94.5%). Among those with R0 resection, 22 were aged ≥75 years and 43 were aged <75 years. PS 1 was significantly more common in the elderly group, with no other baseline differences. Postoperative complications developed in 11 patients (16.9%), including 1 (4.5%) in the elderly group and 10 (23.3%) in the non-elderly group (p = 0.12). Grade III or higher complications occurred only in the non-elderly group. OS and RFS did not differ significantly between the age groups (OS: Hazard ratio (HR) = 0.78, 95% Confidence Interval (CI) 0.27-2.21, p = 0.64; RFS: HR = 1.12, 95% CI 0.51-2.44, p = 0.79). Undifferentiated histology, stage III disease, and poor pathological response were associated with worse survival.
Neoadjuvant SOX therapy is feasible in selected elderly patients with locally advanced gastric cancer and yields survival comparable to those of younger patients.

PMID:
42902061
Bibliographic data and abstract were imported from PubMed on 21 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.